- Home
- WCT vs ERNA Comparison
WCT vs ERNA Comparison
Compare WCT & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- ERNA
- Stock Information
- Founded
- WCT 2012
- ERNA 2018
- Country
- WCT Hong Kong
- ERNA United States
- Employees
- WCT N/A
- ERNA N/A
- Industry
- WCT
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- ERNA Health Care
- Exchange
- WCT NYSE
- ERNA Nasdaq
- Market Cap
- WCT 13.9M
- ERNA 14.5M
- IPO Year
- WCT 2024
- ERNA N/A
- Fundamental
- Price
- WCT $0.30
- ERNA $0.24
- Analyst Decision
- WCT
- ERNA
- Analyst Count
- WCT 0
- ERNA 0
- Target Price
- WCT N/A
- ERNA N/A
- AVG Volume (30 Days)
- WCT 1.7M
- ERNA 173.9K
- Earning Date
- WCT 12-07-2024
- ERNA 05-23-2025
- Dividend Yield
- WCT N/A
- ERNA N/A
- EPS Growth
- WCT N/A
- ERNA N/A
- EPS
- WCT 0.05
- ERNA N/A
- Revenue
- WCT $2,370,163.00
- ERNA $535,000.00
- Revenue This Year
- WCT N/A
- ERNA N/A
- Revenue Next Year
- WCT N/A
- ERNA N/A
- P/E Ratio
- WCT $6.89
- ERNA N/A
- Revenue Growth
- WCT N/A
- ERNA 365.22
- 52 Week Low
- WCT $0.12
- ERNA $0.15
- 52 Week High
- WCT $9.36
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- ERNA 60.91
- Support Level
- WCT N/A
- ERNA $0.19
- Resistance Level
- WCT N/A
- ERNA $0.27
- Average True Range (ATR)
- WCT 0.00
- ERNA 0.02
- MACD
- WCT 0.00
- ERNA 0.01
- Stochastic Oscillator
- WCT 0.00
- ERNA 64.25
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.